U.S. Food and Drug Administration Approves Immix Biopharma Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Joey Cohen
Medication Adherence

Matt Turner
Patient Affordability

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Liz Kane
Impactful Strategy

Paul Theisen
Patient Acquisition